全年营收大增342%背后,亚盛医药-B全球创新与商业化全面提速

智通财经
28 Mar

2024年,港股医药板块受外部因素影响出现较大幅度下跌。例如,在去年9月末强势反弹后,恒生医疗保健指数(800804)的全年跌幅也有18.93%,港股创新药指数(931787)跌幅则在10.80%。在此背景下,亚盛医药-B(06855)股价却在2024年全年股价累涨66.48%,大幅跑赢指数。究其原因,在于2024年亚盛医药频繁在产品出海、创新研发以及二级市场融资等方面出现多重超预期利好,使得公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10